Pharmacologic blockade of FAK autophosphorylation decreases human glioblastoma tumor growth and synergizes with temozolomide

Molecular Cancer Therapeutics

Volumn 12, Issue 2, 2013, Pages 162-172

  Golubovskaya, Vita M ^a,b   Huang, Grace ^a   Ho, Baotran ^a   Yemma, Michael ^a,b   Morrison, Carl D ^a   Lee, Jisook ^c   Eliceiri, Brian P ^c   Cance, William G ^a,b  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b CureFAKtor Pharmaceuticals   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 8; TEMOZOLOMIDE; UNCLASSIFIED DRUG; Y 15;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; AUTOPHOSPHORYLATION; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CELL INVASION; CELL STRUCTURE; CELL SURVIVAL; CELL VIABILITY; CLONOGENESIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; FEMALE; GLIOBLASTOMA; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DACARBAZINE; FEMALE; FOCAL ADHESION PROTEIN-TYROSINE KINASES; GLIOBLASTOMA; HUMANS; MICE; MICE, KNOCKOUT; MICE, NUDE; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; RANDOM ALLOCATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84874031013     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-12-0701     Document Type: Article

References (21)

1. Hecker TP, Grammer JR, Gillespie GY, Stewart J Jr, Gladson CL. Focal adhesion kinase enhances signaling through the Shc/extracellular signal-regulated kinase pathway in anaplastic astrocytoma tumor biopsy samples. Cancer Res 2002; 62:2699-707.
2. Cance WG, Golubovskaya VM. Focal adhesion kinase versus p53: apoptosis or survival? Sci Signal 2008; 1:pe22.
3. Golubovskaya VM, Finch R, Cance WG. Direct interaction of the Nterminal domain of focal adhesion kinase with the N-terminal transactivation domain of p53. J Biol Chem 2005; 280:25008-21.
4. Golubovskaya VM, Cance WG. Focal adhesion kinase and p53 signaling in cancer cells. Int Rev Cytol 2007; 263:103-53.
5. Golubovskaya VM, Cance W. Focal adhesion kinase and p53 signal transduction pathways in cancer. Front Biosci 2010; 15: 901-12.
6. Natarajan M, Stewart JE, Golemis EA, Pugacheva EN, Alexandropoulos K, Cox BD, et al. HEF1 is a necessary and specific downstream effector of FAK that promotes the migration of glioblastoma cells. Oncogene 2006; 25:1721-32.
7. Lee J, Borboa AK, Chun HB, Baird A, Eliceiri BP. Conditional deletion of the focal adhesion kinase FAK alters remodeling of the blood-brain barrier in glioma. Cancer Res 2010; 70:10131-40.
8. Liu T-J, LaFortune T, Honda T, Ohmori O, Katakeyama S, Meyer T, et al. Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo. Mol Cancer Ther 2007; 6:1357-67.
9. Golubovskaya VM, Nyberg C, Zheng M, Kweh F, Magis A, Ostrov D, et al. A small molecule inhibitor, 1,2,4,5-benzenetetraamine tetrahydrochloride, targeting the Y397 site of focal adhesion kinase decreases tumor growth. J Med Chem 2008; 51:7405-16.
10. Beierle EA, Ma X, Stewart J, Nyberg C, Trujillo A, Cance WG, et al. Inhibition of focal adhesion kinase decreases tumor growth in human neuroblastoma. Cell Cycle 2010; 9:1005-15.
11. Hochwald SN, Nyberg C, Zheng M, Zheng D, Wood C, Massoll NA, et al. A novel small molecule inhibitor of FAK decreases growth of human pancreatic cancer. Cell Cycle 2009; 8:2435-43.
12. Hanks SK, Polte TR. Signaling through focal adhesion kinase. Bioessays 1997; 19:137-45.
13. Kruse CA, Mitchell DH, Kleinschmidt-DeMasters BK, Franklin WA, Morse HG, Spector EB, et al. Characterization of a continuous human glioma cell line DBTRG-05MG: growth kinetics, karyotype, receptor expression, and tumor suppressor gene analyses. In Vitro Cell Dev Biol 1992; 28A:609-14.
14. Golubovskaya V, Beviglia L, Xu LH, Earp HS III, Craven R, Cance W. Dual inhibition of focal adhesion kinase and epidermal growth factor receptor pathways cooperatively induces death receptor-mediated apoptosis in human breast cancer cells. J Biol Chem 2002; 277: 38978-87.
15. Eliceiri BP, Paul R, Schwartzberg PL, Hood JD, Leng J, Cheresh DA. Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. Mol Cell 1999; 4:915-24.
16. Lund CV, Nguyen MT, Owens GC, Pakchoian AJ, Shaterian A, Kruse CA, et al. Reduced glioma infiltration in Src-deficient mice. J Neurooncol 2006; 78:19-29.
17. Shai A, Pitot HC, Lambert PF. p53 Loss synergizes with estrogen and papillomaviral oncogenes to induce cervical and breast cancers. Cancer Res 2008; 68:2622-31.
18. Liu W, Bloom DA, Cance WG, Kurenova EV, Golubovskaya VM, Hochwald SN. FAK and IGF-IR interact to provide survival signals in human pancreatic adenocarcinoma cells. Carcinogenesis 2008; 29: 1096-107.
19. Roberts WG, Ung E, Whalen P, Cooper B, Hulford C, Autry C, et al. Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271. Cancer Res 2008; 68:1935-44.
20. Tanjoni I, Walsh C, Uryu S, Tomar A, Nam JO, Mielgo A, et al. PND1186 FAK inhibitor selectively promotes tumor cell apoptosis in threedimensional environments. Cancer Biol Ther 2010; 9:764-77.
21. Walsh C, Tanjoni I, Uryu S, Tomar A, Nam JO, Luo H, et al. Oral delivery of PND-1186 FAK inhibitor decreases tumor growth and spontaneous breast to lung metastasis in pre-clinical models. Cancer Biol Ther 2010; 9:778-90.